Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.08 and traded as high as $8.12. Achieve Life Sciences shares last traded at $8.02, with a volume of 73,152 shares changing hands.
Wall Street Analysts Forecast Growth
Several research firms have commented on ACHV. Oppenheimer reissued an “outperform” rating and issued a $17.00 target price on shares of Achieve Life Sciences in a report on Friday, March 17th. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of Achieve Life Sciences in a research note on Friday, March 17th.
Achieve Life Sciences Trading Down 0.7 %
The business’s 50 day moving average price is $5.79 and its two-hundred day moving average price is $4.08. The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $143.80 million, a price-to-earnings ratio of -1.98 and a beta of 1.51.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last posted its earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same quarter last year, the company earned ($0.76) EPS. On average, equities analysts predict that Achieve Life Sciences, Inc. will post -1.94 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Achieve Life Sciences
Several hedge funds have recently added to or reduced their stakes in ACHV. HRT Financial LP acquired a new position in shares of Achieve Life Sciences in the 4th quarter worth approximately $32,000. Morgan Stanley increased its stake in shares of Achieve Life Sciences by 437.4% in the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 11,026 shares in the last quarter. Prelude Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the 2nd quarter valued at $49,000. Jane Street Group LLC bought a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at $53,000. Finally, Raymond James & Associates increased its stake in shares of Achieve Life Sciences by 34.6% in the 3rd quarter. Raymond James & Associates now owns 17,431 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 4,482 shares in the last quarter. 21.11% of the stock is currently owned by institutional investors and hedge funds.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
See Also
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.